Cargando…

Cisplatin Eligibility Issues and Alternative Regimens in Locoregionally Advanced Head and Neck Cancer: Recommendations for Clinical Practice

Well-designed randomized trials provide the highest level of scientific evidence to guide clinical decision making. In chemoradiotherapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN), data support the use of three cycles of 100 mg/m(2) cisplatin given every 3 weeks concurr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Szturz, Petr, Cristina, Valerie, Herrera Gómez, Ruth Gabriela, Bourhis, Jean, Simon, Christian, Vermorken, Jan B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6579895/ https://www.ncbi.nlm.nih.gov/pubmed/31245288 http://dx.doi.org/10.3389/fonc.2019.00464

Ejemplares similares

Translating KEYNOTE-048 into practice recommendations for head and neck cancer
por: Szturz, Petr, et al.
Publicado: (2020)

Editorial: Head and neck cancer in the elderly
por: Szturz, Petr, et al.
Publicado: (2023)

Immunotherapy in head and neck cancer: aiming at EXTREME precision
por: Szturz, Petr, et al.
Publicado: (2017)

Treatment of Elderly Patients with Squamous Cell Carcinoma of the Head and Neck
por: Szturz, Petr, et al.
Publicado: (2016)

Follow-Up of Head and Neck Cancer Survivors: Tipping the Balance of Intensity
por: Szturz, Petr, et al.
Publicado: (2020)

Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma
por: Cristina, Valerie, et al.
Publicado: (2019)

Low-Dose vs. High-Dose Cisplatin: Lessons Learned From 59 Chemoradiotherapy Trials in Head and Neck Cancer
por: Szturz, Petr, et al.
Publicado: (2019)

Treatment Considerations for Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin
por: Kim, Sangwoo S., et al.
Publicado: (2023)

Oligometastatic Cancer: Key Concepts and Research Opportunities for 2021 and Beyond
por: Szturz, Petr, et al.
Publicado: (2021)

Steering decision making by terminology: oligometastatic versus argometastatic
por: Szturz, Petr, et al.
Publicado: (2022)

Eligibility criteria to cisplatin in head and neck squamous cell carcinoma: Egyptian expert opinion
por: Abdulla, Mohamed, et al.
Publicado: (2023)

Oligometastatic Disease Management: Finding the Sweet Spot
por: Szturz, Petr, et al.
Publicado: (2020)

Estimating the Prevalence of a True Oligometastatic Disease
por: Szturz, Petr, et al.
Publicado: (2022)

Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma
por: Chen, Tien-Hua, et al.
Publicado: (2022)

Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma
por: Fayette, Jérôme, et al.
Publicado: (2015)

Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323)
por: van Herpen, C M L, et al.
Publicado: (2010)

Hyperfractionated Radiotherapy with Concurrent Cisplatin/5-Fluorouracil for Locoregional Advanced Head and Neck Cancer: Analysis of 105 Consecutive Patients
por: Zaboli, David, et al.
Publicado: (2012)

Quality of life analysis of patients treated with cetuximab or cisplatin for locoregionally advanced squamous cell carcinoma of head and neck in the United States
por: Aggarwal, Himani, et al.
Publicado: (2020)

The role of cisplatin alternative regimens with radiotherapy in cervical cancer
por: Chen, Yi-Ju Amy, et al.
Publicado: (2014)

Assessment and topographic characterization of locoregional recurrences in head and neck tumours
por: Ferreira, Brigida Costa, et al.
Publicado: (2015)

Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy
por: Marín-Jiménez, Juan A., et al.
Publicado: (2022)

Matched pair analysis for comparison of survival outcome of alternative regimens to standard three-weekly cisplatin-based concurrent chemoradiation of head and neck cancer
por: Han, Hye Ri, et al.
Publicado: (2021)

Induction gemcitabine and cisplatin in locoregionally advanced nasopharyngeal carcinoma
por: Zhang, Yuan, et al.
Publicado: (2019)

Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial
por: Burtness, Barbara, et al.
Publicado: (2014)

Neoadjuvant chemotherapy with different dose regimens of docetaxel, cisplatin and fluorouracil (TPF) for locoregionally advanced nasopharyngeal carcinoma: a retrospective study
por: Jin, Ting, et al.
Publicado: (2017)

Few eligible for the newly recommended short course MDR-TB regimen at a large Mumbai private clinic
por: Udwadia, Zarir F., et al.
Publicado: (2019)

Clinical efficacy of neoadjuvant chemotherapy with platinum-based regimen for patients with locoregionally advanced head and neck squamous cell carcinoma: an evidence-based meta-analysis
por: Chen, Hui, et al.
Publicado: (2011)

Cutaneous Angiosarcoma of Head and Neck: A New Predictive Score for Locoregional Metastasis()()
por: Gründahl, J.E.H., et al.
Publicado: (2015)

Salvage Carbon-Ion Radiation Therapy For Locoregionally Recurrent Head and Neck Malignancies
por: Gao, Jing, et al.
Publicado: (2019)

Editorial: Insights in head and neck cancer: 2021
por: Lybaert, Willem, et al.
Publicado: (2023)

ARTSCAN III: A Randomized Phase III Study Comparing Chemoradiotherapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer
por: Gebre-Medhin, Maria, et al.
Publicado: (2021)

Is Gemcitabine and Cisplatin Induction Chemotherapy Superior in Locoregionally Advanced Nasopharyngeal Carcinoma?
por: Zheng, Wei, et al.
Publicado: (2015)

Efficacy and Safety of Systemic and Locoregional Cisplatin Chronotherapy in Rats with Ovarian Carcinoma
por: Kireeva, Galina, et al.
Publicado: (2021)

Head and Neck Cancer
por: Psyrri, Amanda, et al.
Publicado: (2009)

Nephrotoxicity as a Dose-Limiting Factor in a High-Dose Cisplatin-Based Chemoradiotherapy Regimen for Head and Neck Carcinomas
por: Hoek, Jantien, et al.
Publicado: (2016)

Biologic Therapy in Head and Neck Cancer: A Road with Hurdles
por: Specenier, Pol, et al.
Publicado: (2012)

Cetuximab: its unique place in head and neck cancer treatment
por: Specenier, Pol, et al.
Publicado: (2013)

Optimizing induction chemotherapy regimens for radiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma
por: Li, Ying, et al.
Publicado: (2023)

Cisplatin and Fluorouracil Induction Chemotherapy With or Without Docetaxel in Locoregionally Advanced Nasopharyngeal Carcinoma()()()()
por: Jin, Ting, et al.
Publicado: (2019)

Locoregional Control and Survival in Children, Adolescents, and Young Adults With Localized Head and Neck Alveolar Rhabdomyosarcoma—The French Experience
por: Machavoine, Roxane, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_plqoscqrpap8m124vhbo8hj35p